天津科学技术出版社

IKZF1突变型急性B淋巴细胞白血病造血干细胞移植研究进展

王佳丽 1,2,张荣莉 1,2,姜尔烈 1,2 *
作者信息
  1. 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020
  2. 2 天津医学健康研究院,天津 301600
*通信作者

摘要

急性B淋巴细胞白血病(B-ALL)是一种在遗传学和临床预后上具有高度异质性的恶性血液系统肿瘤。近年来,高通量测序技术的广泛应用揭示了大量与疾病发生、发展和治疗反应相关的分子标志物。其中,IKZF1基因编码的Ikaros转录因子,作为淋巴系发育的核心调控因子,其突变被证实是独立不良预后因素之一。IKZF1突变与化疗耐药、高微小残留病(MRD)负荷及疾病早期复发密切相关,异基因造血干细胞移植(allo-HSCT)是改善此类患者预后的关键治疗手段。本文系统综述了IKZF1突变的分子机制、流行病学及临床特征,深入探讨HSCT的适应证、移植时机、预处理方案及移植全程管理策略,并展望了风险分层精准化、预处理方案个体化及新型治疗手段与HSCT整合的未来方向。


Frontier advances on hematopoietic stem cell transplantation for IKZF1-mutant B-acute lymphoblastic leukemia

Jiali WANG 1,2, Rongli ZHANG 1,2, Erlie Jiang 1,2 *
Author Information
  1. 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
  2. 2 Tianjin Institutes of Health Science, Tianjin 301600, China
*Corresponding author

Abstract

B-acute lymphoblastic leukemia (B-ALL) is a malignant hematologic disorder characterized by high heterogeneity in both genetics and clinical prognosis. In recent years, the widespread application of high-throughput sequencing technologies has revealed a large number of molecular markers associated with disease initiation, progression, and treatment response. Among these, the IKZF1 gene, which encodes the Ikaros transcription factor, a central regulator of lymphoid development, has drawn particular attention. Deletions or mutations of IKZF1 have been established as independent adverse prognostic factors. IKZF1 mutation is significantly associated with chemotherapy resistance, high minimal residual disease (MRD) burden, and early disease relapse, rendering allogeneic hematopoietic stem cell transplantation (allo-HSCT) during first complete remission (CR1) a pivotal strategy for improving survival outcomes in these patients. This review aims to systematically elucidate the functional roles and biological characteristics of IKZF1 mutations, critically analyze the evidence-based data in risk stratification, transplant decision-making, MRD management strategies and explore the prospects of emerging therapeutic approaches – including targeted therapies and immunotherapies. The goal is to provide a comprehensive theoretical framework and practical reference for precision treatment of IKZF1-mutated B-ALL.

再生医学研究 Copyright © 2026. All Rights Reserved